NCT03138577 is a Phase 4 clinical trial of Ultrasound Imaging in Surgery of Right Upper Extremity, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT03138577?

NCT03138577 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT03138577?

Interventions in NCT03138577: Ultrasound Imaging, Supraclavicular Block, Bedside Negative Inspiratory Force Meter.

What condition does NCT03138577 study?

NCT03138577 studies Surgery of Right Upper Extremity.

Is NCT03138577 still recruiting?

NCT03138577 is currently completed. Last updated 13 May 2020.

Are results published for NCT03138577?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-05-13 · How we verify

NCT03138577

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-Response Relationships for Hemidiaphragmatic Paresis Following Ultrasound-Guided Supraclavicular Block

Completed Phase 4 Results posted Last updated 13 May 2020

What this trial tests

Phase 4 trial testing Ultrasound Imaging in Surgery of Right Upper Extremity in 24 participants. Completed in 30 July 2019.

Timeline

12 February 2018

Primary endpoint
30 July 2019

30 July 2019

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	24
Start date	12 February 2018
Primary completion	30 July 2019
Estimated completion	30 July 2019
Sites	1 location across United States

Drugs / interventions tested

Ultrasound Imaging
Supraclavicular Block — full drug profile →
Bedside Negative Inspiratory Force Meter

Conditions studied

Surgery of Right Upper Extremity — all drugs for Surgery of Right Upper Extremity →

Sponsor

Weill Medical College of Cornell University

Who can join

Adults 18 to 105, any sex, with Surgery of Right Upper Extremity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Subjects With Hemidiaphragmatic Paresis at Various Volumes of Local Anesthetic 15 Minutes After Supraclavicular Block Primary · 15 minutes

Diaphragm motion was recorded during voluntary sniffing fifteen minutes after supraclavicular block with the specified volume of local anesthetic. Blinded investigators reviewed the scans and determined whether the scans were indicative of hemidiaphragmatic paresis (HDP) or not (No HDP). This data was fit to a dose response curve.

Group	Value	95% CI
Dose Cohort 7 (5 mL)	1
Dose Cohort 6 (10 mL)	1
Dose Cohort 5 (15 mL)	1
Dose Cohort 4 (20 mL)	2
Dose Cohort 3 (25 mL)	2
Dose Cohort 2 (30 mL)	3
Dose Cohort 1 (35 mL)	3
Dose Cohort 7 (5 mL)	2
Dose Cohort 6 (10 mL)	2
Dose Cohort 5 (15 mL)	2
Dose Cohort 4 (20 mL)	1
Dose Cohort 3 (25 mL)	1
Dose Cohort 2 (30 mL)	0
Dose Cohort 1 (35 mL)	0

Number of Subjects With Hemidiaphragmatic Paresis at Various Volumes of Local Anesthetic 30 Minutes After Supraclavicular Block Primary · 30 minutes

Diaphragm motion was recorded during voluntary sniffing 30 minutes after supraclavicular block with the specified volume of local anesthetic. Blinded investigators reviewed the scans and determined whether the scans were indicative of hemidiaphragmatic paresis (HDP) or not (No HDP). This data was fit to a dose response curve.

Group	Value	95% CI
Dose Cohort 7 (5 mL)	1
Dose Cohort 6 (10 mL)	1
Dose Cohort 5 (15 mL)	1
Dose Cohort 4 (20 mL)	2
Dose Cohort 3 (25 mL)	3
Dose Cohort 2 (30 mL)	3
Dose Cohort 1 (35 mL)	3
Dose Cohort 7 (5 mL)	2
Dose Cohort 6 (10 mL)	2
Dose Cohort 5 (15 mL)	2
Dose Cohort 4 (20 mL)	1
Dose Cohort 3 (25 mL)	0
Dose Cohort 2 (30 mL)	0
Dose Cohort 1 (35 mL)	0

Change in Negative Inspiratory Force (NIF) at 30 Minutes Secondary · 30 minutes

The change of the absolute value of NIF from the baseline measurement to that at 30 minutes after the block

Group	Value	95% CI
Subjects With HDP	-7.5	-22.0 – 0
Subjects Without HDP	0	-10 – 0

Dose Response Curve for Motor and Sensory Block 15 Minutes After Block Secondary · 15 minutes

As described in the protocol, each subject's block was assessed via motor and sensory exam at 15 minutes and given a score (0-20), with 20 being a perfect block and any score less than 10 indicating an ineffective block. A dose response curve was generated for block score with different volumes of local anesthetic administered.

Subject 1/3

Group	Value	95% CI
Dose Cohort 7 (5 mL)	1
Dose Cohort 6 (10 mL)	11
Dose Cohort 5 (15 mL)	7
Dose Cohort 4 (20 mL)	2
Dose Cohort 3 (25 mL)	20
Dose Cohort 2 (30 mL)	15
Dose Cohort 1 (35 mL)	11

Subject 2/3

Group	Value	95% CI
Dose Cohort 7 (5 mL)	12
Dose Cohort 6 (10 mL)	12
Dose Cohort 5 (15 mL)	0
Dose Cohort 4 (20 mL)	1
Dose Cohort 3 (25 mL)	19
Dose Cohort 2 (30 mL)	15
Dose Cohort 1 (35 mL)	15

Subject 3/3

Group	Value	95% CI
Dose Cohort 7 (5 mL)	10
Dose Cohort 6 (10 mL)	0
Dose Cohort 5 (15 mL)	18
Dose Cohort 4 (20 mL)	0
Dose Cohort 3 (25 mL)	5
Dose Cohort 2 (30 mL)	16
Dose Cohort 1 (35 mL)	19

Dose Response Curve for Motor and Sensory Block Score 30 Minutes After Block Secondary · 30 minutes

As described in the protocol, each subject's block was assessed via motor and sensory exam at 30 minutes and given a score (0-20), with 20 being a perfect block and any score less than 10 indicating an ineffective block. A dose response curve was generated for block score with different volumes of local anesthetic administered.

Subject 1 of 3

Group	Value	95% CI
Dose Cohort 7 (5 mL)	2
Dose Cohort 6 (10 mL)	14
Dose Cohort 5 (15 mL)	8
Dose Cohort 4 (20 mL)	20
Dose Cohort 3 (25 mL)	20
Dose Cohort 2 (30 mL)	14
Dose Cohort 1 (35 mL)	15

Subject 2 of 3

Group	Value	95% CI
Dose Cohort 7 (5 mL)	18
Dose Cohort 6 (10 mL)	14
Dose Cohort 5 (15 mL)	2
Dose Cohort 4 (20 mL)	10
Dose Cohort 3 (25 mL)	20
Dose Cohort 2 (30 mL)	16
Dose Cohort 1 (35 mL)	18

Subject 3 of 3

Group	Value	95% CI
Dose Cohort 7 (5 mL)	10
Dose Cohort 6 (10 mL)	12
Dose Cohort 5 (15 mL)	18
Dose Cohort 4 (20 mL)	16
Dose Cohort 3 (25 mL)	16
Dose Cohort 2 (30 mL)	16
Dose Cohort 1 (35 mL)	19

Change in Room Air Oxygen Saturation at 30 Minutes. Secondary · 30 minutes

The change in room air oxygen saturation from baseline to 30 minutes after the block was calculated.

Group	Value	95% CI
Subjects With HDP	-1	-2 – 0
Subjects Without HDP	0	0 – 0

Subjective Dyspnea 30 Minutes After Block Secondary · 30 minutes

30 minutes after the block, patients were asked to rate any symptoms of dyspnea on a scale of 0 (no trouble breathing) to 10 (extreme trouble breathing).

Group	Value	95% CI
Subjects With HDP	0	0 – 2
Subjects Without HDP	0	0 – 0

Sponsor's own description

This clinical trial is for subjects undergoing right upper extremity surgery. The aim of the study is to investigate the dose-response relationship between local anesthetic volume and ipsilateral hemidiaphragmatic paresis (HDP) in patients getting ultrasound-guided supraclavicular brachial plexus blocks in a blinded, prospective trial.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dose-response relationship between local anesthetic volume and hemidiaphragmatic paresis following ultrasound-guided supraclavicular brachial plexus blockade.
Tedore TR, Lin HX, Pryor KO, Tangel VE, et al · · 2020 · cited 20× · PMID 33004656 · DOI 10.1136/rapm-2020-101728

Verify or expand the search:

Other trials of Ultrasound Imaging

Trials testing the same drug.

NCT07281547 — Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometr · Phase 4 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT06999798 — An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast · Phase 1 · recruiting
NCT06735664 — Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation · Phase 1 · recruiting
NCT06635980 — Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer · Phase 2 · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03138577 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 13 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03138577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing